Double Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage
A Randomized Controlled Trial of Double Simultaneous Uterotonic Agents (Misoprostol Plus Intravenous Oxytocin) Versus Single Agent Regimen (Intravenous Oxytocin Only) to Prevent Early Postpartum Hemorrhage
Stony Brook University
1,358 participants
Jan 27, 2025
INTERVENTIONAL
Conditions
Summary
To determine the effectiveness of using two medications simultaneously versus one medication, as is standard of care, in preventing early postpartum hemorrhage. There have been studies that looked at giving two medications and that there were reduced odds of postpartum hemorrhage. Specific Aim 1: Determine if double simultaneous uterotonic agent regimen (misoprostol and oxytocin) is superior to single agent (oxytocin only) in reducing postpartum hemorrhage. Specific Aim 2: Determine any potential side effects of a double simultaneous uterotonic agentregimen (misoprostol and oxytocin) versus a single agent (oxytocin only).
Eligibility
Inclusion Criteria1
- \- All women 18 years and older admitted to delivery at Stony Brook University hospital who agree to participate in the study
Exclusion Criteria5
- Women under 18 years old
- Women with known coagulation disorders
- Women with planned cesarean hysterectomy
- Women with known placental accreta spectrum disorders
- Women with known allergy to prostaglandins
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Misoprostol 400 mcg sublingual
40 units IV Oxytocin in 1000 mL normal saline
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05245227